JAK1-selective kinase inhibitor

in clinical development for cancer

from HTS and SBDD of promiscuous hit

J. Med. Chem., Apr. 28, 2020

AstraZeneca, Waltham, MA

AZD4205 is a JAK1-selective kinase inhibitor which is in clinical development for oncology rather than the inflammatory diseases most JAK1 inhibitors have aimed for. The compound has excellent PK in…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.